Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
QL0911, a recombinant human thrombopoietin mimetic peptide-Fc fusion protein for injection, is a romiplostim (Nplate®) biosimilar for the treatment of primary immune thrombocytopenia (ITP). This phase III study aimed to assess the efficacy and safety of QL0911 in adult patients with primary chronic ITP.
Epistemonikos ID: d5b2fa0089ba692a26fb25792033b963398508ce
First added on: May 14, 2024